article thumbnail

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Cannabis Law Report

Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year 1.

article thumbnail

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Cannabis Law Report

3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. In the United States, the estimated cost of hospitalizations in individuals with sarcopenia is estimated at $40.4

article thumbnail

Skin Cancer Drugs Global Market Report 2021: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma – ResearchAndMarkets.com

Cannabis Law Report

billion in 2025 at a CAGR of 14%. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. The market is expected to reach $2.72 The skin cancer drugs market consists of sales of skin cancer drugs.

article thumbnail

Oregon proposes only using one type of mushroom for new psilocybin system, and no pills

Cannabis Law Report

Measure 109 called on the state to only license people who have been Oregon residents for at least two years, until 2025. They have a couple of pieces that they need to report back on in relation to safety, social impact, review of any new or ongoing clinical trials,” Backstrom said.

article thumbnail

Where Does The FDA Stand on CBD and CBD Products?

The Joint Blog

organic food market by 2025 is at $70.4 The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To It has been predicted that the U.S CBD Products and the FDA The U.S.

CBD 33